Single-dose sodium polystyrene sulfonate for hyperkalemia in chronic kidney disease or end-stage renal disease

BACKGROUND: The use of sodium polystyrene sulfonate (SPS) for the treatment of hyperkalemia lacks sufficient efficacy data in patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD); however, use remains widespread. Recent evidence suggests that this population may be at risk f...

Descripción completa

Detalles Bibliográficos
Autores principales: Hunt, Taylor V, DeMott, Joshua M, Ackerbauer, Kimberly A, Whittier, William L, Peksa, Gary D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
CKD
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6543963/
https://www.ncbi.nlm.nih.gov/pubmed/31198541
http://dx.doi.org/10.1093/ckj/sfy063

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6543963/
https://www.ncbi.nlm.nih.gov/pubmed/31198541
http://dx.doi.org/10.1093/ckj/sfy063

Ejemplares similares